VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LEGNLegend Biotech Corporation
$16.11$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LEGN logo

Legend Biotech Corporation

LEGN
NASDAQ · Cell & Gene Therapy
$16.11
At close - Nov 17, 4:00 PM EST - USD
Market Cap$2.98B
P/E-9999.0x
52W High$37.50
Volume3.02M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Carvykti Scale-Up Turns Operating Profit but Cash Burn Persists

Legend Biotech's revenue has grown from $160.2M in 2024Q3 to $359.5M in 2026Q3 as Carvykti gains commercial traction, and operating margin moved from -43.7% to 13.0% over the same period, suggesting operating leverage is beginning to emerge.

GrowthExpanding
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

LEGN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-41342% Peers

P/E is 41342% below peer median

03

Market leadership

RS 27 · Lag

Laggard (Underperforming 73% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 10
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue expanded to $359.5M in 2026Q3 with operating margin turning positive at 13.0%, but gross margin compressed from 73.0% in 2024Q2 to 58.9%, suggesting rising per-patient costs may be absorbing part of the top-line gains.

Analyst Consensus+278.6% target
Buy(20 analysts)
14 Buy6 Hold0 Sell

The Bull Case

Upside Catalysts

Innovative therapies

Legend Biotech is focused on developing cutting-edge treatments for hematological malignancies and solid tumors, driving long-term shareholder value.

Clinical updates

Regular clinical updates and presentations at key events like ASCO highlight progress in Legend Biotech's pipeline.

SEC filings transparency

Comprehensive SEC filings provide detailed insights into CARVYKTI sales, governance, and risk disclosures, enhancing investor confidence.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LEGN-25.10%
S&P 500 (^GSPC)+7.21%
1-Year Return
LEGN-45.79%
S&P 500 (^GSPC)+10.03%
3-Year Return
LEGN-75.05%
S&P 500 (^GSPC)+61.80%
5-Year Return
LEGN-71.09%
S&P 500 (^GSPC)+51.10%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-9999.0x
Forward P/E
N/A
EV/EBITDA
29.5x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-9999.0x
N/A
N/A
EV/EBITDA
29.5x
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$9.20-42.9%
Base (Fair)$49.19+181.1%
Bull$15.13-6.1%
$9.20 Bear$49.19 Base$15.13 Bull
Current Market Price: $16.11
Trades at a 67.2% discount to Base DCF ($49.19)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.03B+64.0% YoY
Net income FY25
-$297M-67.7% YoY
Free cash flow FY25
-$168M-6.3% YoY
Operating margin FY25
-13.3%+35.1 pts YoY
ROIC (FY25)-12.7%
Avg ROIC 5Y-98.1%
ROE (TTM)-0%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 10, 2026
$0.14+1300.0%
vs $0.01
$360M-0.5%
vs $361M
Q3 2026
Aug 11, 2026
$0.09-25.0%
vs $0.12
$388M+8.9%
vs $356M
Q2 2026
May 12, 2026
-$0.15-650.0%
vs -$0.02
$305M-0.5%
vs $307M
Q2 2026
Mar 10, 2026
-$0.08+52.9%
vs -$0.17
$306M-0.5%
vs $308M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·23h ago
Legend Biotech: The Market Is Missing The Bigger Picture

Legend Biotech Corporation shares have plunged 34.5% after briefly rallying to $24.3 on November 9, partly amid the broader selloff in AI-related stocks. I continue to take advantage of market pessimism by steadily accumulating LEGN. Sales of LEGN's blockbuster, Carvykti, developed jointly with J&J, increased 8.1% quarter-on-quarter to $710 million.

Seeking Alpha·Nov 10, 2026
Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript

MarketBeat·Nov 10, 2026
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech NASDAQ: LEGN reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line U.S. patients and international launch delays could temper sales expectations.

GlobeNewsWire·Nov 10, 2026
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI ® infusion, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM Updated NCCN Guidelines recommend that all patients with multiple myeloma be referred to a T-cell therapy capable center at first relapse for consideration of available therapies Received U.S. FDA IND clearance for LB2501, an investigational CD19/CD20 dual-targeting in vivo CAR‑T therapy for relapsed or refractory B-cell malignancies Appointed Ingrid Zhang as Chief Executive Officer Cash and cash equivalents, and time deposits of approximately $853 million, as of September 30, 2026 BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2026 unaudited financial results and recent highlights.

Filtered for Legend Biotech CorporationMore Headlines
04

Compare before deciding

Benchmark LEGN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Legend Biotech Corporation (LEGN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LEGN logoLEGNLegend Biotech CorporationCurrent
$16.11$2.98B-9999.0064.04%-0.02%-0.02%—
FATE logoFATEFate Therapeutics, Inc.
$1.02$118.89M-1.01-51.24%-2619.64%-73.92%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.15$3.87B-8.52-89.97%-1812.07%-25.59%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.78$1.1B-3.2216.92%-805.75%-64.73%—
EDIT logoEDITEditas Medicine, Inc.
$1.83$280.07M-3.8825.39%-144.95%-130.43%—

Compare LEGN vs Peers

Legend Biotech Corporation (LEGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for LEGN.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare LEGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, CRSP, BEAM, NTLA

Get notified when LEGN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LEGN Frequently Asked Questions

Legend Biotech Corporation (LEGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Legend Biotech Corporation's revenue?

Legend Biotech Corporation (LEGN) reported $1.36B in revenue over the trailing twelve months. Revenue was $1.03B in fiscal year 2025. That is 4261% more than the $23.6M of fiscal year 2017.

How fast is Legend Biotech Corporation growing?

Legend Biotech Corporation (LEGN) grew revenue by 49.5% over the trailing twelve months, compared with the twelve months before.

Is LEGN profitable?

No. Legend Biotech Corporation (LEGN) reported a net loss of $0.2M over the trailing twelve months.

Dividend & Returns
What is LEGN's return on equity?

Legend Biotech Corporation (LEGN) had a return on equity (ROE) of -0.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Legend Biotech Corporation's free cash flow?

Legend Biotech Corporation (LEGN) had negative free cash flow of $320.9M over the trailing twelve months.

What if you invested $1,000 in LEGN back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →